The Food and Drug Administration approved Ubrelvy, the company’s ubrogepant treatment, on Monday. The oral medication is aimed at treating migraines in patients who are unresponsive to common migraine treatments, such as triptans, or are at risk of cardiovascular disorders. Allergan, which anticipated a December approval by the FDA, said Ubrelvy will be available for sale in the U.S. in the first quarter.
Some migraines can be treated with over-the-counter medications such as ibuprofen, acetaminophen or aspirin, if taken at the first signs of a migraine occurring. When these aren't effective, the most commonly prescribed treatment is a class of drugs called triptans, which are considered more effective than ubrogepant but have a catch: They work by constricting blood vessels around the brain to stop the pain, so they are not considered safe for use by people at risk of cardiovascular disease and stroke. The newly approved drug, on the other hand, has a different molecular target -- a protein involved in the transmission of pain.